IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides.
Dupilumab, an existing asthma and skin-disease drug, shows mechanistic potential against cutaneous T-cell lymphoma through suppression of cancer cell growth pathways.
Ex vivo skin explant experiments with IL4Rα blockade (dupilumab) in advanced-stage mycosis fungoides, combined with CITEseq and machine learning, reveal that REGN668 suppresses both malignant T cell proliferation (PI3K/AKT, JAK/STAT, cell cycle) and immunosuppressive stromal cells. Patient-specific heterogeneity suggests combination strategies will be needed, but provides strong mechanistic rationale for dupilumab repurposing in cutaneous T cell lymphoma.
What the study was
- Study design
- Ex vivo mechanistic study with single-cell transcriptomics
- Population
- Advanced-stage mycosis fungoides patients (cutaneous T cell lymphoma)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Journal for ImmunoTherapy of Cancer
Why it surfaced
Novel repurposing of dupilumab (FDA-approved anti-IL4Rα) for cutaneous T cell lymphoma with mechanistic single-cell evidence; addresses high unmet need (5yr OS 25% in advanced MF).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.